Acute Lymphoid Leukemia Clinical Trial
— MILAOfficial title:
Etude du Microenvironnement médullaire Dans Les Leucémies Aiguës de l'Enfant
Acute leukemia (AL) is the most common cancer in children. Despite the optimization of chemotherapy treatments and the development of supportive care, a certain number of LAs relapse and/or progress to death of the child. It therefore seems essential to try to better understand the physiopathology and the mechanisms of resistance to treatment of these diseases.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | October 24, 2028 |
Est. primary completion date | October 25, 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 1 Year to 15 Years |
Eligibility | Inclusion Criteria: - for patients with AL: 1. Child with acute lymphoblastic or myeloblastic leukemia at diagnosis 2. Not having received prior hematological treatment 3. Aged 1 to 15 years old 4. Whose 2 parents, or the holder of parental authority, have signed a consent enlightened. 5. Affiliated patient or beneficiary of a social security scheme. - Control group patients: 1. Child undergoing orthopedic surgery exposing the bone marrow (osteotomy of the pelvis). 2. Aged between 1 and 15 years old. 3. Having no pathology of hematological origin. 4. Not having received any treatment that could interfere with the functioning of the bone marrow. 5. Whose 2 parents or the holder of parental authority have signed a consent enlightened. 6. Affiliated patient or beneficiary of a social security scheme. Exclusion Criteria: - for patients with AL: 1. Patient under 1 year old and over 15 years old. 2. Contraindication to myelogram. 3. Absence of signature of the informed consent by the 2 parents or the holder of parental authority. 4. Patients with relapsed acute lymphoblastic or myeloblastic leukemia. 5. Having received prior hematological treatments. 6. Parents with physical or mental condition not allowing to understand the informed consent. - Control group patients 1. Patient under 1 year old and over 15 years old. 2. Having an underlying haematological pathology. 3. Absence of signature of the informed consent by the 2 parents or the holder of parental authority. 4. Having received prior hematological treatments. 5. Parents with physical or mental condition not allowing to understand informed consent. |
Country | Name | City | State |
---|---|---|---|
France | Service d'hématologie biologique-CHRU TOURS | Tours | |
France | Service d'onco-hématologie pédiatrique -CHRU Tours | Tours | |
France | Service de chirurgie orthopédique pédiatrique -CHRU TOURS | Tours |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Tours |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Oxygen Consumption Rate | Difference in oxidative phosphorylation measured by OCR (Oxygen Consumption Rate) in pmol/min/nd DNA between the mesenchymal stromal stem cells (MSCs) of children with Acute Leukemia and those of children without blood diseases. | At inclusion | |
Secondary | Difference in Extra Cellular Acidification Rate | Difference in glycolysis, measured by the ECAR (Extra Cellular Acification Rate) in mpH/min/ng DNA between the MSCs of children with AL and those of children without hematological disease. | At inclusion | |
Secondary | Difference in Reactive Oxygen Species | Difference in oxidative metabolism thanks to the measurement of reactive oxygen species (ROS), measured in MIF/isotype, between MSCs of children with AL and those of children without hematological disease | At inclusion | |
Secondary | Difference in doubling time in culture | The difference in doubling time in culture (measured in days) between the MSCs of children with LA and those of children free of hemopathy. At each passage, the number of living and dead MSCs will be counted. | At inclusion | |
Secondary | Difference in Immunophenotypic profile | The difference in immunophenotypic profile (cytometry, immunofluorescence) between MSCs of children with AL and those of children without hematological disease. Use of a panel of monoclonal antibodies directed against various membrane antigens (CD45, CD34, CD14, CD90, CD73, CD105). | At inclusion | |
Secondary | Difference in mutational profiles between MSCs and leukemia cells | Difference in mutational profiles between MSCs and leukemia cells from children with AL. Comparison of mutations acquired by leukemic cells compared to stromal cells by an NGS-type high-throughput sequencing approach. | At inclusion | |
Secondary | Differences in transcriptomic signatures between MSCs and MSC subpopulations | Differences in transcriptomic signatures between MSCs and MSC subpopulations of children with AL and those of children without hematological disease. The RNAs of the MSCs obtained after culture will be extracted then reverse-transcribed into cDNA. The quality control of the extracted RNAs will be carried out on a Bioanalyzer (Agilent). Transcriptome analysis of the MSC pool will be performed by RNA Seq/NGS. Transcriptomic identification of MSC subpopulations will be performed by single-cell RNAseq/NGS. | At inclusion | |
Secondary | Differences in cytokine profiles within the bone marrow | Differences in cytokine profiles in the bone marrow and in the blood, measured in ng/mL, between children with AL and children without hematological disease.ELISA-like assay of IL-3, IL-6, IL-7, IL-8, IL-10, IL-15, TGF-bĂȘta, IFN-gamma | At inclusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05959720 -
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
|
||
Recruiting |
NCT02933333 -
G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor
|
Phase 4 | |
Completed |
NCT02953730 -
The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents
|
Phase 4 | |
Completed |
NCT02767388 -
Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery
|
||
Recruiting |
NCT03610438 -
Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia
|
Phase 2 | |
Completed |
NCT02294552 -
Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT
|
Phase 2 | |
Completed |
NCT01461538 -
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
|
Phase 2 | |
Recruiting |
NCT04167683 -
Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant
|
||
Recruiting |
NCT05150561 -
Muscle Dysfunction in Patients With Haematological Diseases
|
||
Active, not recruiting |
NCT04669210 -
PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT
|
Phase 2 | |
Active, not recruiting |
NCT04013685 -
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
|
Phase 1 | |
Recruiting |
NCT02345915 -
Evaluation of Adverse Long-term Effects in Young Adult Survivors of Acute Leukemia
|
N/A | |
Completed |
NCT01720264 -
Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant
|
Phase 2 | |
Not yet recruiting |
NCT02413021 -
The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens
|
Phase 1 | |
Not yet recruiting |
NCT06427330 -
Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia
|
Phase 2 | |
Active, not recruiting |
NCT04778579 -
Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy
|
Phase 2 | |
Recruiting |
NCT03448393 -
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
|
Phase 1 | |
Completed |
NCT03833180 -
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
|
Phase 1 | |
Active, not recruiting |
NCT03367299 -
Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT02435550 -
iCare for Cancer Patients
|
N/A |